GlaxoSmithKline plc ($GSK) announced data for its Nucala trial. The company said that patients with severe asthma, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, in comparison to patients treated with placebo and standard of care.
GlaxoSmithKline said that the results from the phase IIIb MUSCA study (NCT02281318, 200862), show that the trial successfully met all its primary and secondary endpoints. The results are expected to provide fillip to the company stock price which has already gained over 8 percent this year so far. Its 12 months gain stands at close to 7 percent.
The exploratory endpoints for the trial were the annual rate of exacerbations (asthma attacks), which was reduced by 58%. Another endpoint was the number of exacerbations requiring emergency room visits or hospitalisation, which was reduced by 68% for people treated with mepolizumab compared with placebo.
GlaxoSmithKline recently reported the appointment of Emma Walmsley as its incoming CEO. Walmsley is currently serving as the CEO of Consumer Healthcare business of the company. She will join as the CEO of GlaxoSmithKline on April.